Article Text

Download PDFPDF

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
  1. Matteo Lambertini1,2,
  2. Angela Toss3,
  3. Antonio Passaro4,
  4. Carmen Criscitiello5,
  5. Chiara Cremolini6,
  6. Claudia Cardone7,8,
  7. Fotios Loupakis9,
  8. Giuseppe Viscardi8,10,
  9. Icro Meattini11,12,
  10. Maria Vittoria Dieci13,14,
  11. Roberto Ferrara10,
  12. Raffaele Giusti15,
  13. Massimo Di Maio16,17
  1. 1 Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy
  2. 2 Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy
  3. 3 Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
  4. 4 Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
  5. 5 New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, Milan, Italy
  6. 6 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
  7. 7 Clinical Trials Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Naples, Italy
  8. 8 Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy
  9. 9 Department of Oncology, Unit of Oncology 1, Oncologic Institute of Veneto IRCCS, Italy
  10. 10 Department of Medical Oncology, Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  11. 11 Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy
  12. 12 Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
  13. 13 Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
  14. 14 Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
  15. 15 Medical Oncology Unit, Sant’Andrea Hospital of Rome, Rome, Italy
  16. 16 Department of Oncology, University of Turin, Turin, Italy
  17. 17 Medical Oncology, Mauriziano Hospital, Turin, Italy
  1. Correspondence to Dr Matteo Lambertini; matteo.lambertini{at}unige.it
  • editorial
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @matteolambe

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer Matteo Lambertini acted as consultant for Roche and Lilly, and received speaker honoraria from Roche, Takeda and Theramex outside the submitted work. Angela Toss acted as consultant for Eisai, Roche and Lilly outside the submitted work. Antonio Passaro acted as consultant for AstraZeneca, Agilent/Dako, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme and Roche. Carmen Criscitiello received speakers’ bureau and had consultancy/advisory role from Lilly, Roche Novartis, and Pfizer outside the submitted work. Chiara Cremolini acted as consultant for Roche, Bayer and Amgen, and received personal fees from Roche, Amgen, Bayer, Servier, and research funding from Merck Serono. Icro Meattini acted as consultant for Roche, Novartis, and Lilly outside the submitted work. Maria Vittoria Dieci acted as consultant for Eli Lilly, Genomic Health and Celgene outside the submitted work. Raffaele Giusti acted as consultant and received speaker honoraria for Roche and Astra Zeneca outside the submitted work. Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work. The other authors declare no conflicts of interests.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.